Resistance to fluoroquinolones among clinical isolates of Staphylococcus aureus has become a clinical problem. Therefore, a rapid method to identify S. aureus and its susceptibility to fluoroquinolones could provide clinicians with a useful tool for the appropriate use of these antimicrobial agents in the health care settings. In this study, we developed a rapid real-time PCR assay for the detection of S. aureus and mutations at codons Ser-80 and Glu-84 of the grlA gene encoding the DNA topoisomerase IV, which are associated with decreased susceptibility to fluoroquinolones. The detection limit of the assay was 10 genome copies per reaction. The PCR assay was negative with DNA from all 26 non-S. aureus bacterial species tested. A total of 85 S. aureus isolates with various levels of fluoroquinolone resistance was tested with the PCR assay. The PCR assay correctly identified 100% of the S. aureus isolates tested compared to conventional culture methods. The correlation between the MICs of ciprofloxacin, levofloxacin, and gatifloxacin and the PCR results was 98.8%. The total time required for the identification of S. aureus and determination of its susceptibility to fluoroquinolones was about 45 min, including DNA extraction. This new rapid PCR assay represents a powerful method for the detection of S. aureus and its susceptibility to fluoroquinolones.
In recent years, the clinical efficacy of fluoroquinolones against infections with Staphylococcus aureus has been undermined by the widespread emergence of decreased susceptibility to these compounds (1, 8) . Resistance to fluoroquinolones, and in particular to ciprofloxacin, is considerably higher among methicillin-resistant S. aureus (MRSA) strains than among methicillin-susceptible S. aureus strains (8) . Indeed, 60 to 90% of the MRSA organisms isolated worldwide are now resistant to ciprofloxacin (3) . Recently, considerable efforts have been made to improve the spectra of activity of quinolones against S. aureus, including MRSA. New fluoroquinolones, such as levofloxacin, gatifloxacin, and moxifloxacin, have been developed and are presently on the market. However, despite their improved activities, newer fluoroquinolones have been shown to be less active against ciprofloxacin-resistant bacteria, and an increased resistance to these new compounds has been observed, especially with MRSA strains (8) .
Fluoroquinolone resistance in S. aureus has been well studied and is associated, in most isolates, with single mutations in DNA topoisomerase IV and DNA gyrase (8, 25) . Resistance mutations most often occur within the quinolone resistancedetermining regions located in the grlA and gyrA genes encoding the A subunits of topoisomerase IV and DNA gyrase, respectively. In S. aureus, DNA topoisomerase IV is the primary target of fluoroquinolones, and first-step resistance to most of these antimicrobial agents has been associated with mutations in grlA (8, 25) . Indeed, data from various studies have shown that most S. aureus isolates having decreased susceptibility to fluoroquinolones harbor mutations at codons 80 (Ser-80 to Phe or Tyr) and/or 84 (Glu-84 to Lys or Val or Gly) of grlA (23, 26, 27, 30) . Single mutations in grlA appear to be sufficient to reach MICs of ciprofloxacin that exceed the laboratory breakpoints for susceptibility (8) . On the other hand, for new fluoroquinolones, single grlA mutations are associated with a reduced susceptibility to these compounds but are not sufficient for clinical resistance. Additional mutations in gyrA and, less commonly, in grlB and gyrB, encoding the B subunits of the DNA topoisomerase IV and DNA gyrase, respectively, will usually generate full resistance to new fluoroquinolones and an increased level of ciprofloxacin resistance (8) . In addition to mutations in these loci, altered expression of norA, a gene encoding a multidrug efflux pump, can also confer lowlevel resistance to fluoroquinolones (8, 25) . It has been shown that S. aureus isolates with existing first-step grlA mutations are more likely to acquire subsequent mutations that result in clinical resistance to the new fluoroquinolones (5) . Therefore, the development of novel methods that can rapidly identify mutations in the S. aureus grlA gene would provide a useful tool for the appropriate use of new fluoroquinolones in clinical settings.
In this study, we describe a rapid real-time PCR assay for the detection of S. aureus and of mutations in the grlA gene associated with fluoroquinolone resistance. We compare this PCR assay with conventional culture methods for identification of S. aureus isolates and determination of their susceptibility to fluoroquinolones.
(This study was partially presented at the 101st General (14) with primers grlA205 and grlA396 ( Table  1 ). The PCR products were purified and sequenced as previously described (14) .
Nucleotide sequence accession number. GenBank accession numbers for the 220-bp partial sequence of the S. aureus grlA gene are as follows: AY234038 for strain ATCC 25923, AY214125 for strain ATCC 29213, AY214123 for strain CCRI-2024, AY214124 for strain CCRI-12876, AY214128 for strain 9015, AY214127 for strain 9191, AY214126 for strain 9283, and AY214129 for strain 9299.
RESULTS
Specificity and sensitivity of the PCR assay. In this study, we have developed a PCR primer pair (grlA205 and grlA396) specific to the S. aureus grlA gene and three fluorescent MBPs that allow the detection of the amplified grlA gene product (Sau-TET) together with mutations at codons 80 (S80-FAM) and 84 (E84-FAM) of this gene. Two PCRs were performed for each assay. In the first reaction, the S. aureus grlA-specific primer pair was combined with the Sau-TET and S80-FAM probes, whereas in the second reaction, this primer pair was combined with the Sau-TET and E84-FAM probes. The specificity of the real-time PCR assay for S. aureus was first demonstrated with a panel of 27 bacterial species (31 strains) genetically close to S. aureus (Table 2) . DNA from all bacterial species other than S. aureus were PCR negative, showing that this assay is specific to S. aureus. The specificity of the PCR assay for the detection of mutations at codons 80 and 84 of the S. aureus grlA gene was then tested against eight S. aureus strains with or without mutations in grlA ( Table 2 ). 
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shows an example of the detection of fluoroquinolone-sensitive and -resistant S. aureus strains on a Smart Cycler. A positive fluorescent signal was detected with the three probes for the fluoroquinolone-sensitive strain with no mutation at codons 80 and 84 of grlA, whereas a positive signal was detected with the Sau-TET probe only for the fluoroquinolone-resistant strain with mutations at both codons. The assay correctly identified the six S. aureus strains with mutations at codons 80 and/or 84 of grlA (Table 2) . It also correctly identified the two S. aureus strains with no mutation at these codons. The analytical sensitivity of the assay was determined by using genomic DNA purified from three S. aureus strains with or without mutations at codons 80 and/or 84 of grlA. The detection limit was about 10 genomic copies per PCR (data not shown).
Correlation between PCR and conventional culture methods. We have compared the results of conventional culture methods for identification of S. aureus and the susceptibility to ciprofloxacin, levofloxacin, and gatifloxacin determined by the Etest method for 85 S. aureus clinical isolates from various geographic areas with those obtained by the PCR assay. For these 85 S. aureus strains, MICs ranged from 0.094 to Ͼ32 g/ ml for ciprofloxacin and levofloxacin and from 0.047 to Ͼ32 g/ml for gatifloxacin. All S. aureus strains tested were correctly identified by PCR. Correlation between fluoroquinolone susceptibility and the presence of mutations in grlA is summarized in Table 3 . Of the 85 S. aureus strains tested, 35 (41.2%) were susceptible to ciprofloxacin (MIC, Յ1 g/ml). All these strains were negative for mutation at codons 80 and 84 based on PCR. Of the 50 ciprofloxacin-resistant strains (58.8%) (ciprofloxacin MIC, Ն2 g/ml), 49 had mutations at codons 80 and/or 84 detected by PCR. No mutation was detected in grlA in one ciprofloxacin-resistant strain. Thirty-seven S. aureus 
a All PCR tests were performed using 0.1 ng of purified genomic DNA. b These strains were chosen to represent different mutations at codons 80 and 84 of grlA. The quinolone resistance-determining regions of grlA from these strains were sequenced in this study. S. aureus strains ATCC 25923 and ATCC 29213 have no mutation at codons 80 and 84; strains CCRI-2024, 9191, and 9299 have a Ser-80-to-Phe (TCC3TTC) mutation; strain 9015 has a Glu-84-to-Gly (GAA3GGA) mutation; strain 9283 has a Glu-84-to-Lys (GAA3AAA) mutation; and strain CCRI-12876 has both Ser-80-to-Tyr (TCC3TAC) and Glu-84 to Gly (GAA3GGA) mutations. strains (43.5%) were susceptible to levofloxacin (MIC, Յ2 g/ ml). No mutation was detected in grlA for 36 of these strains. One levofloxacin-sensitive strain had a mutation at codon 84 of grlA detected by PCR. Forty-eight strains (56.5%) were resistant to levofloxacin (MIC, Ն4 g/ml), and all had mutations at codons 80 and/or 84 detected by PCR. Of the 37 S. aureus strains (43.5%) susceptible to gatifloxacin (MIC, Յ2 g/ml), 36 were negative for mutation at codons 80 and/or 84 by PCR. A mutation was detected at codon 84 of grlA by PCR in one gatifloxacin-sensitive strain. Forty-eight S. aureus strains (56.5%) were resistant to gatifloxacin (MIC, Ն4 g/ml), and all had mutations at codons 80 and/or 84 detected by PCR. Overall, among the 49 S. aureus strains with mutations in grlA, 26 (53%) had a mutation at codon 80, 2 (4.1%) had a mutation at codon 84, and 21 (42.9%) had mutations at both codons.
DISCUSSION
The emergence of fluoroquinolone resistance in S. aureus is of great concern. In the treatment of staphylococcal infections, fluoroquinolones should not be administered empirically but only after determination of the antimicrobial susceptibility of the clinical isolates. For these reasons, it has become important to develop rapid diagnostic tests to monitor the clinical utility of fluoroquinolones and also to minimize the emergence of resistance. Many molecularly-based tests have been recently developed to identify S. aureus and to determine its susceptibility to various antibiotics (10, 11, 17, 22) . While all these tests detected the presence of a specific gene to establish the antibiotic susceptibility profile, mutations in the targets of fluoroquinolones must be detected to determine the susceptibility to this class of antibiotics.
In the present study, we developed a rapid real-time PCR assay that can be used to simultaneously identify S. aureus and the first-step mutations associated with decreased susceptibility to fluoroquinolones. This assay is based on the detection of the S. aureus grlA gene encoding the A subunits of DNA topoisomerase IV and of mutations at codons Ser-80 and/or Glu-84, which are associated with fluoroquinolone resistance. We have compared the PCR assay for the detection of S. aureus and mutations in grlA with classical methods for identification of S. aureus and determination of susceptibility to fluoroquinolones. Overall, we found correlations between these methods of 100% for S. aureus identification and of 98.8% for ciprofloxacin, levofloxacin, or gatifloxacin susceptibility testing. Two strains did not show any correlation between the PCR results and the MICs. One ciprofloxacin-resistant strain, for which the ciprofloxacin MIC was 2 g/ml, had no mutation, based on PCR. The decreased susceptibility to ciprofloxacin in this strain may be associated with other resistance mechanisms, such as NorA efflux pump-mediated resistance or mutations in other regions of grlA (12, 19, 23, 24) . Another strain which was resistant to ciprofloxacin, for which the ciprofloxacin MIC was 4 g/ml, had a mutation at codon 80 but was clinically susceptible to levofloxacin and gatifloxacin (MICs, 1.5 and 0.75 g/ ml, respectively). However, the MICs of these two antibiotics were six to eight times higher than those for the fluoroquinolone-sensitive S. aureus control strain ATCC 29213, showing that the former strain exhibits reduced susceptibility to these fluoroquinolones. The low level of resistance to ciprofloxacin and reduced susceptibility to the new fluoroquinolones suggested that this strain may have a single mutation at codon 80 of grlA. Therefore, these data corroborated those from others which have shown that a single grlA mutation is not sufficient to cause clinical resistance to levofloxacin and gatifloxacin but greatly decreased the susceptibility to these antimicrobial agents (9, 30 ).
In the method described in this study, mutations in gyrA, gyrB, or grlB were not sought. However, detection of mutations in grlA provided an excellent correlation with susceptibility to all the fluoroquinolones tested. The good correlation between grlA mutations and resistance to gatifloxacin and levofloxacin may be explained by accumulation of mutations in both grlA and gyrA genes in the strains studied. Indeed, 96% (49 of 51) of the fluoroquinolone-resistant S. aureus isolates tested in this study exhibited high-level resistance to ciprofloxacin (MIC, Ͼ8 g/ml). This high level of resistance is usually associated with mutations in grlA as well as in gyrA, gyrB, and/or grlB genes which generate cross-resistance to new fluoroquinolones (4, 9, 26) . Among the 85 S. aureus isolates studied, 56 were resistant to oxacillin (MRSA strains). Forty-six (82.1%) of the 56 MRSA isolates exhibited resistance to both ciprofloxacin (MIC, Ͼ32 g/ml) and new fluoroquinolones, whereas only three of the forty (7.5%) methicillin-susceptible S. aureus isolates exhibited this resistance phenotype. Therefore, these data suggest a high prevalence of resistance to the new fluoroquinolones among MRSA isolates, as also described recently by other groups (7, 23) . The high prevalence of fluoroquinolone resistance among MRSA isolates has been attributed to both selection by quinolone exposure and transmission of clonal strains in health care settings (8) . The increasing resistance of S. aureus isolates to new fluoroquinolones suggests that physicians should be cautious when using these antibiotics, especially against isolates with grlA mutations, as the potential to acquire subsequent mutations that lead to full resistance is higher in those strains (5). The PCR assay described in this study should therefore provide a useful tool for the appropriate use of new fluoroquinolones against S. aureus infections.
In the real-time PCR assay developed in this study, fluorescent MBPs were used to detect the S. aureus grlA gene and the mutations associated with fluoroquinolone resistance. MBPs are fluorescently labeled single-stranded nucleic acid probes that possess a stem-loop structure (28) . It has been shown that the structure of MBPs allows a more effective detection of single-nucleotide polymorphisms over a wide range of temperatures than do the corresponding linear probes, such as TaqMan probes (2) . MBPs have been used in several applications, including detection of mutations associated with antibiotic resistance, such as mutations in the rpoB gene of Mycobacterium tuberculosis that confer resistance to the antibiotic rifampin (21) . Other groups have used adjacent probes or TaqMan probes for the detection of gyrA mutations associated with ciprofloxacin resistance in gram-negative bacteria (15, 16, 29, 31 ). The present study shows that our MBPs were highly specific for detection of single-nucleotide polymorphisms in the S. aureus grlA gene associated with fluoroquinolone resistance.
Several methodological approaches for the detection of mutations in the S. aureus targets of fluoroquinolones, such as sequencing, single-strand conformation polymorphism, restriction fragment length polymorphism, and denaturing high-performance liquid chromatography, have been developed (6, 18, 27, 30) . Because of the complexity and the time required to perform the experiments, these methods are not appropriate for routine use in clinical microbiology laboratories. The use of the real-time PCR assay described here greatly decreased the time required to identify S. aureus isolates and to detect the grlA mutations associated with reduced susceptibility to fluoroquinolones compared to conventional methods. The procedure, including DNA extraction, can be completed in less than 1 h. Furthermore, this PCR assay was sensitive, as it detected as few as 10 genome copies per PCR, showing that its potential for detection of S. aureus directly from clinical specimens.
With a correlation of 98.8% between the MICs and the PCR assay for all three fluoroquinolones tested, this real-time PCR assay represents a promising diagnostic tool that can replace conventional culture methods for rapid identification of S. aureus along with susceptibility testing against fluoroquinolones.
